Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Search research articles

Related Experiment Videos

Rapamycin analogs with reduced systemic exposure.

Rolf Wagner¹, Karl W Mollison, Luping Liu

¹Abbott Laboratories, Global Pharmaceutical Research and Development, Abbott Park, IL 60064, USA. rolf.wagner@abbott.com

Bioorganic & Medicinal Chemistry Letters

|September 28, 2005

Summary

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Addressing the Challenges of Translating LRRK2 Biology into Disease-Modifying Therapies: The LRRK2 Investigative Therapeutics Exchange Initiative.

Movement disorders : official journal of the Movement Disorder Society·2026

Same author

Seed dormancy cycling: A driver of germination timing in a facultative winter annual.

Plant diversity·2026

Same author

Fine mapping and candidate gene analysis of a major QTL qHSW_11 for seed weight in soybean.

TAG. Theoretical and applied genetics. Theoretische und angewandte Genetik·2026

Same author

Toll-like receptor 4 mediates lipopolysaccharide-induced emesis.

British journal of pharmacology·2026

Same author

Developmental Toxicity of Chlorinated Polyfluorinated Ether Sulfonate (F-53B), a Perfluorooctane Sulfonate (PFOS) Alternative, in Embryos and Larvae of Blotched Snakehead (<i>Channa maculata</i>).

Antioxidants (Basel, Switzerland)·2026

Same author

Structural mechanism of substrate binding and inhibition of human taurine transporter.

Nature communications·2026

Same journal

Synthesis and biological investigation of phenothiazine-based derivatives as potential HDAC6 inhibitors for treatment of glioblastoma multiforme.

Bioorganic & medicinal chemistry letters·2026

Same journal

Solid-phase synthesis and antimicrobial activities of lipid-neomycin conjugates.

Bioorganic & medicinal chemistry letters·2026

Same journal

Discovery of a potent sGC stimulator with once-daily dosing potential for the treatment of hypertension.

Bioorganic & medicinal chemistry letters·2026

Same journal

OracleScreen-LILRB4 (HTS-Oracle v3): machine learning-guided discovery of myeloid immune checkpoint binders validated in patient-derived cells.

Bioorganic & medicinal chemistry letters·2026

Same journal

Rational design and N-terminal acylation of a lactam-cyclized 11-residue antimicrobial peptide for improved antibacterial potency.

Bioorganic & medicinal chemistry letters·2026

Same journal

Rational design, synthesis, and biological evaluation of chalcone hybrids including benzoylpiperazin (phenylacetylpiperazin)-thiophene as anti- Alzheimer's agents.

Bioorganic & medicinal chemistry letters·2026

See all related articles

This summary is machine-generated.

New rapamycin analogs modified at the C-40 position were synthesized. These compounds may offer a better safety profile due to a shorter in vivo half-life than rapamycin.

Area of Science:

Medicinal Chemistry
Pharmacology

Background:

Rapamycin is an immunosuppressant drug with a narrow therapeutic index.
Modifications to the rapamycin structure are being explored to improve its safety profile.

Purpose of the Study:

To synthesize and evaluate novel rapamycin analogs with modifications at the C-40 position.
To investigate if these C-40 modified analogs exhibit improved pharmacokinetic properties, specifically a shorter in vivo half-life.

Main Methods:

Chemical synthesis of rapamycin analogs.
In vitro and in vivo biological activity assays.
Pharmacokinetic studies to determine half-life.

Main Results:

Successful synthesis of several C-40 modified rapamycin analogs.

Related Experiment Videos

Preliminary data suggests some analogs possess comparable or altered biological activity to rapamycin.

Initial pharmacokinetic assessments indicate a potentially reduced in vivo half-life for certain analogs.

Conclusions:

C-40 modification of rapamycin is a viable strategy for developing analogs.
The synthesized analogs warrant further investigation for their therapeutic potential and improved safety profile.
A shorter in vivo half-life may contribute to an enhanced safety profile for these rapamycin derivatives.